 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...1112131415161718192021...266267» |
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Checkpoint inhibition: GVAX Plus Checkpoint Blockade in Neuroblastoma (clinicaltrials.gov) - May 13, 2024
P1, N=19, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting
- || Adcetris (brentuximab vedotin) / Takeda, Pfizer, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Clinical, Journal, Checkpoint inhibition: Distinct autoantibody profiles across checkpoint inhibitor types and toxicities. (Pubmed Central) - May 13, 2024
P1/2
We conclude that dynamic autoantibody profiles may differ according to ICI category and irAE type. These findings may have relevance to clinical monitoring and irAE treatment.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, Checkpoint inhibition: A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer (clinicaltrials.gov) - May 13, 2024
P2, N=65, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Monotherapy: CheckMate 032: A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - May 12, 2024
P1/2, N=1163, Active, not recruiting, Sponsor: Bristol-Myers Squibb
These findings may have relevance to clinical monitoring and irAE treatment. Trial completion date: May 2024 --> Oct 2024
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: High Serum Levels of CCL20 Are Associated with Recurrence and Unfavorable Overall Survival in Advanced Melanoma Patients Receiving Immunotherapy. (Pubmed Central) - May 11, 2024
CCL20 may represent a novel blood-based biomarker for the prediction of resistance to immunotherapy that can be used in combination with established strong clinical predictors (e.g., ECOG performance score) and laboratory markers (e.g., S100) in advanced melanoma patients. Future prospective randomized trials are needed to establish CCL20 as a liquid biopsy-based biomarker in advanced melanoma.
- || Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date: CheckMate 142: A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (clinicaltrials.gov) - May 10, 2024
P2, N=385, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Future prospective randomized trials are needed to establish CCL20 as a liquid biopsy-based biomarker in advanced melanoma. Trial completion date: Feb 2024 --> Jun 2024 | Trial primary completion date: Feb 2024 --> Jun 2024
- || Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical, Journal, Metastases: Nivolumab?+?Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial. (Pubmed Central) - May 9, 2024
P2
However, added high-dose ipilimumab may improve tumor response and survival in patients with mUC. ClinicalTrials.gov Identifier: NCT03219775.
- | Keytruda (pembrolizumab) / Merck (MSD), Leukine (sargramostim) / Partner Therap, Yervoy (ipilimumab) / BMS
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: ABSCOPAL 5001: A Phase 2 Trial for Patients With Metastatic Solid Cancer (clinicaltrials.gov) - May 9, 2024
P2, N=32, Active, not recruiting, Sponsor: Rampart Health, L.L.C.
ClinicalTrials.gov Identifier: NCT03219775. Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - May 8, 2024
P1, N=29, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Trial completion date: Mar 2024 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Mar 2026
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date: A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650) (clinicaltrials.gov) - May 8, 2024
P2, N=351, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Mar 2024 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Mar 2026 Trial completion date: May 2024 --> Jan 2025
- ||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical, P3 data, Clinical Trial,Phase III, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial. (Pubmed Central) - May 8, 2024
P3
Trial completion date: May 2024 --> Jan 2025 Nivolumab plus chemotherapy and nivolumab plus ipilimumab continued to demonstrate clinically meaningful OS benefit versus chemotherapy with no new safety signals identified with longer follow-up, further supporting use as first-line standard treatment options for patients with advanced ESCC.
- ||||| sitravatinib (MGCD516) / BeiGene
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study (clinicaltrials.gov) - May 8, 2024
P2/3, N=55, Active, not recruiting, Sponsor: Mirati Therapeutics Inc.
Nivolumab plus chemotherapy and nivolumab plus ipilimumab continued to demonstrate clinically meaningful OS benefit versus chemotherapy with no new safety signals identified with longer follow-up, further supporting use as first-line standard treatment options for patients with advanced ESCC. Enrolling by invitation --> Active, not recruiting | N=200 --> 55 | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
PET-Based Total Body Assessment of Response to Immunotherapy in Melanoma (Exhibit Hall D - Science Pavilion (Convention Center); Screen 41; In-Person Only) - May 8, 2024 - Abstract #SNMMI2024SNMMI_1964;
This decrease in FDG uptake potentially signifies a reduction in cancer burden following immunotherapy and good therapy response. TBP imaging appears to be very effective in detecting and quantifying cancer-related disease activity at baseline and following immunotherapy.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Combination therapy, Real-world evidence, Real-world, Metastases: Real-world outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma in Japanese patients: data with a minimum of 3 (Pubmed Central) - May 7, 2024
The 3-year follow-up data showed that nivolumab plus ipilimumab combination therapy exhibited a feasible effectiveness in real-world Japanese patients with advanced renal cell carcinoma. Accordingly, the high risk of adverse event development, which often requires treatment withdrawal and corticosteroid administration, should be considered.
- | Yervoy (ipilimumab) / BMS
Trial completion, Trial completion date, Trial primary completion date: Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies (clinicaltrials.gov) - May 6, 2024
P2, N=41, Completed, Sponsor: M.D. Anderson Cancer Center
Accordingly, the high risk of adverse event development, which often requires treatment withdrawal and corticosteroid administration, should be considered. Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> May 2024 | Trial primary completion date: Mar 2025 --> May 2024
- | Journal, Metastases: Advanced melanoma with low-burden and low-risk disease: a clinical case. (Pubmed Central) - May 6, 2024
Patients with low tumor burden and low-risk disease (i.e., with normal LDH levels), having higher survival rates and probability of good outcome to systemic therapy, represent a challenge for the clinician, deserving the attempt to reach long-term complete responses. The following case report is quite representative of the above-mentioned clinical situation.
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion, Trial completion date, Trial primary completion date, Tumor mutational burden: Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) (clinicaltrials.gov) - May 5, 2024
P2, N=81, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
The following case report is quite representative of the above-mentioned clinical situation. Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Apr 2024 | Trial primary completion date: Sep 2024 --> Apr 2024
- | BMS-986218 / BMS, Opdivo (nivolumab) / BMS
Enrollment change, Trial termination: First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - May 3, 2024
P1/2, N=512, Terminated, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Apr 2024 | Trial primary completion date: Sep 2024 --> Apr 2024 N=390 --> 512 | Active, not recruiting --> Terminated; Business Objectives have changed.
- | Opdivo (nivolumab) / BMS, Cdactin-O (CBM588) / Osel, Miyarisan, Yervoy (ipilimumab) / BMS
New P1 trial: CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer (clinicaltrials.gov) - May 3, 2024
P1, N=28, Recruiting, Sponsor: City of Hope Medical Center
- ||| Opdivo (nivolumab) / BMS, vidutolimod (CMP-001) / Regeneron
Biomarker, Enrollment closed, Enrollment change, Trial completion date: Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab (clinicaltrials.gov) - May 3, 2024
P2, N=9, Active, not recruiting, Sponsor: Diwakar Davar
N=390 --> 512 | Active, not recruiting --> Terminated; Business Objectives have changed. Suspended --> Active, not recruiting | N=36 --> 9 | Trial completion date: Jul 2030 --> Jul 2028
- || Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
P1/2 data, Journal, Metastases: Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial. (Pubmed Central) - May 2, 2024
P1/2
Nivolumab monotherapy and nivolumab plus ipilimumab combination therapy showed promise in the CheckMate 358 study as potential treatment options for recurrent or metastatic cervical cancer. Future randomised controlled trials of nivolumab plus ipilimumab or other dual immunotherapy regimens are warranted to confirm treatment benefit in this patient population.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Biomarker, Trial completion date: Lung-Map Sub-Study: Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (clinicaltrials.gov) - May 2, 2024
P3, N=275, Active, not recruiting, Sponsor: SWOG Cancer Research Network
Future randomised controlled trials of nivolumab plus ipilimumab or other dual immunotherapy regimens are warranted to confirm treatment benefit in this patient population. Trial completion date: Apr 2024 --> Apr 2025
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: ADAPT-IT: A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy (clinicaltrials.gov) - May 1, 2024
P2, N=70, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Apr 2024 --> Apr 2025 Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Checkpoint inhibition, Cytokine release syndrome: Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer: A Case Report. (Pubmed Central) - May 1, 2024
Organ damage was gradually controlled with immunosuppressive drugs, including steroids, and the patient was discharged. Successful treatment is rare in patients with CRS, including ICANS, during immune checkpoint inhibitor treatment for solid tumors.
- | Amtagvi (lifileucel) / Iovance Biotherap
Journal: Lifileucel (Amtagvi): A cellular therapy for melanoma. (Pubmed Central) - May 1, 2024
Successful treatment is rare in patients with CRS, including ICANS, during immune checkpoint inhibitor treatment for solid tumors. No abstract available
- | Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Checkpoint inhibition, Metastases: Unanticipated pathological clearance in two cases of clinical T4b dMMR/MSI-h advanced colorectal cancer: the potential of immune checkpoint inhibitors despite positive positron-emission tomography results. (Pubmed Central) - May 1, 2024
However, it remains unknown whether ICI therapy can replace surgery or diminish the optimal extent of resection, or whether adjuvant chemotherapy is needed after surgery in the case of achieving pCR after ICI therapy. Overall, this case report suggests that ICI before colorectal surgery can be effective and potentially a 'watch-and-wait" strategy could be used for cases in which ICI is effective.
- ||| tobemstomig (RG6139) / Roche, tiragolumab (RG6058) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) (clinicaltrials.gov) - May 1, 2024
P1/2, N=110, Completed, Sponsor: Hoffmann-La Roche
Overall, this case report suggests that ICI before colorectal surgery can be effective and potentially a 'watch-and-wait" strategy could be used for cases in which ICI is effective. Recruiting --> Completed | N=336 --> 110 | Trial completion date: Jul 2025 --> Mar 2024 | Trial primary completion date: Jan 2025 --> Sep 2023
- | Intron A (interferon ?-2b) / Merck (MSD), Biogen, Yervoy (ipilimumab) / BMS
Trial completion date: E1609: Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery (clinicaltrials.gov) - Apr 29, 2024
P3, N=1673, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- | Erleada (apalutamide) / J&J, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Metastases: A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. (Pubmed Central) - Apr 29, 2024
Despite the addition of carboplatin+cabazitaxel, men in the Unsatisfactory group had shortened survivals. Adaptive designs can enrich for biologically and clinically relevant disease subgroups, to contribute to the development of marker-informed, risk-adapted therapy strategies in men with prostate cancer.
- |||| Yervoy (ipilimumab) / Ono Pharma, BMS
New P1/2 trial: NEPI: Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer (clinicaltrials.gov) - Apr 28, 2024
P1/2, N=58, Not yet recruiting, Sponsor: University Hospital, Essen
- || Review, Journal: Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas. (Pubmed Central) - Apr 28, 2024
Other combination therapies include pembrolizumab (targeting programed cell death protein 1) and axitinib (a VEGFR and PDGFR blocker) or lenvatinib (a multikinase inhibitor). Since the KEYNOTE-426 clinical trial, the use of immune checkpoint inhibitors in combination with protein-tyrosine kinase inhibitors is now the standard of care for most patients with metastatic renal cell carcinomas and monotherapies are used only in those individuals who cannot receive or tolerate immune checkpoint inhibitors.
- || Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
P2 data, Journal, Checkpoint inhibition, Checkpoint block: A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. (Pubmed Central) - Apr 28, 2024
P2
B cell infiltration was associated with higher densities of regulatory T cells before treatment, which was lost upon ICB treatment. Our data demonstrate that neoadjuvant ICB is associated with complex immune changes within the tumor microenvironment in DDLPS and UPS and that neoadjuvant ICB with concurrent radiotherapy has significant efficacy in UPS.
- || Retrospective data, Review, Journal: Evaluation of First-line and Salvage Therapies for Unresectable Malignant Mesothelioma: A Systematic Review and Network Meta-Analysis. (Pubmed Central) - Apr 28, 2024
Ramucirumab and chemotherapy was associated with the best clinical outcomes in salvage settings. Treatment for malignant mesothelioma should be tailored based on different clinicopathological characteristics.
- | Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date, Checkpoint inhibition: Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases (clinicaltrials.gov) - Apr 26, 2024
P1, N=10, Recruiting, Sponsor: Emory University
Treatment for malignant mesothelioma should be tailored based on different clinicopathological characteristics. Trial primary completion date: Mar 2024 --> Mar 2025
- | Erleada (apalutamide) / J&J, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: DynaMO: Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Apr 26, 2024
P2, N=196, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Mar 2024 --> Mar 2025 Trial completion date: May 2025 --> Mar 2026 | Trial primary completion date: May 2025 --> Mar 2026
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial termination: Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary (clinicaltrials.gov) - Apr 25, 2024
P1, N=1, Terminated, Sponsor: Abramson Cancer Center at Penn Medicine
Trial completion date: May 2025 --> Mar 2026 | Trial primary completion date: May 2025 --> Mar 2026 Active, not recruiting --> Terminated; failure to accrue
- || Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Review, Journal, BRCA Biomarker, PD(L)-1 Biomarker, IO biomarker: Advances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights. (Pubmed Central) - Apr 25, 2024
This review accentuates the transformative capacity of immunotherapy in revolutionizing the therapeutic outlook for MPM, thereby potentially translating into augmented survival rates and offering glimpses of new approaches on the horizon. Despite the persisting challenges, the synergistic crossroads of interdisciplinary research and collaborative clinical endeavors portend a hopeful landscape for MPM treatment.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change: NCI-2016-00661: Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 25, 2024
P1/2, N=80, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Despite the persisting challenges, the synergistic crossroads of interdisciplinary research and collaborative clinical endeavors portend a hopeful landscape for MPM treatment. N=45 --> 80
- |||| Libtayo (cemiplimab-rwlc) / Regeneron
Trial primary completion date, Metastases: EMPOWER-Lung 3: Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer (clinicaltrials.gov) - Apr 25, 2024
P3, N=790, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
N=45 --> 80 Trial primary completion date: Jul 2023 --> Feb 2025
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche, Yervoy (ipilimumab) / BMS
Preliminary safety data of the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial assessing the triple combination atezolizumab-bevacizumab-ipilimumab in patients (pts) treated in systemic therapy for hepatocellular carcinoma (HCC). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6905;
P2/3
The DSMB's decision to continue the trial underscores the potential of this innovative therapeutic approach in improving outcomes for HCC patients. These findings support further investigation into the efficacy and long-term safety of the triple combination therapy in a broader patient population.
- Opdivo (nivolumab) / BMS
Nivolumab monotherapy and associations in the treatment of advanced unresectable biliary tract cancer (BTC): A systematic review and meta-analysis. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6823;
New trials of NIVO + associations with better standardized outcomes and comparative arms for different associations and populations will help to better clarify the effects of NIVO in the treatment of advanced unresectable BTC. >CR = complete response, PR = partial response, SD = stable disease, OR = objective response, DC = disease control, RCT = Randomized Clinical Trial, NIVO = nivolumab.
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
The efficacy of immune checkpoint inhibitors as a part of multimodality treatment in soft tissue and bone sarcoma in an academic community setting. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6805;
CR and PR rates in this setting were high, and responses were durable, although selection bias for treatment may have played a role. This data supports the treatment of metastatic sarcoma with ICI, especially with concomitant RT and surgery, in a variety of subtypes.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Dual immune checkpoint inhibition with nivolumab and ipilimumab (N+I) in patients with advanced anaplastic thyroid carcinoma (ATC). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6751;
P2
High ORR was seen with PD-L1 TPS ?50. Survival outcomes and genomic biomarkers, currently under investigation, will be presented at the meeting.
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Brain metastases in patients with pleural mesothelioma receiving dual checkpoint blockade compared to single-agent checkpoint blockade or chemotherapy. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6587;
The presence of edema suggests a possible immune infiltrate while on IO (correlative studies in progress). Brain imaging should be considered prior to starting IO in patients with PM.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Quality of life outcomes in patients with resectable dedifferentiated liposarcoma treated with neoadjuvant immunotherapy. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6566;
Common themes that emerged demonstrated a lack of severe symptoms experienced by patients in either arm and resolution of symptoms by one year post treatment. Our interview results can help clinicians focus on symptoms that are impactful to patients in future clinical trials.
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Update on the prognostic value of a novel immune-related toxicity grading system (OST score) in patients with advanced solid tumours treated with immune checkpoint inhibitors (ICI). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6417;
Our new score manages to efficiently capture immune-mediated toxicity profile of patients treated with ICI as well as predict their outcomes. Further prospective evaluation, integration of laboratory markers and external validation is currently ongoing.
- The pan-cancer landscape of SMARCA4 and SMARCB1 alterations in a large cohort of Chinese patients. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6384;
The presence of co-mutations may also aid in predicting the efficacy of combination immunotherapy treatments. Furthermore, the high prevalence of VUS emphasizes the need for additional research to determine their clinical relevance.
- Cardiotoxicity of immune checkpoint inhibitors: A retrospective cohort study of 93,362 patients. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6367;
This study suggests a significant association between the use of immunotherapy agents and the development of myocarditis and pericarditis. Further studies are necessary to better delineate the mechanism by which these cardiac toxicities occur, establish guidelines for surveillance of its onset, and discover how to suppress the immune-toxicities while retaining anti-tumor effect.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
NeoRad(Low): A phase 2 trial of neoadjuvant (NA) ipilimumab + nivolumab (ipi+nivo) with low dose stereotactic body radiation therapy (SBRT) as an immune stimulant in patients with resectable stage IB-III non-small cell lung cancer (NSCLC). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6316;
P2
Standard and exploratory biomarkers of immune response will be presented to determine if patient selection played a role in these results. Clinical trial information: NCT04933903.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Impact of time-of-day administration of immunotherapy on overall survival among patients with metastatic renal cell carcinoma. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6065;
This is the first work in a Mexican population. Although larger prospective and controlled studies are necessary, early ICI infusion is a practical, safe and reasonable strategy that could be considered in the treatment of Mexican patients with metastatic renal cell cancer.